Video - Results from #10

REVIEW UroToday

Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives VL

Search

Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich Details John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
Advancing Radiopharmaceuticals: Isotopes, Targets, and Challenges - Germo Gericke Details Oliver Sartor discusses radiopharmaceuticals with Germo Gericke. Dr. Gericke emphasizes the potential of targeted radioligand therapies, particularly for advanced cancers. He explores various isotopes, including Lutetium, Terbium, and Actinium, highlighting Actinium's promise in preclinical studies. Dr. Gericke discusses ideal target characteristics and Ariceum's innovative approach of targeting i...
Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor Details Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67 Cu), for targeted therapy. He explains the company's innovative bisPSMA technology, which offers improved tumor uptake and retention compared to conventional PSMA agents. Dr. Taylor highlights Clarity's work...
Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies - Michael Schultz Details Oliver Sartor speaks with Michael Schultz about advances in radiopharmaceuticals for cancer treatment. Dr. Schultz discusses the advantages of using alpha-particle emitters, particularly lead-212, for targeted cancer therapy. He explains the rationale behind choosing lead-212, including its short half-life and the ability to use lead-203 for imaging. Dr. Schultz addresses distribution challenges a...
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff Details Oliver Sartor speaks with Philip Kantoff about the future of radiopharmaceuticals in cancer treatment. Dr. Kantoff discusses the rationale behind using antibody-based approaches for PSMA-targeted therapies, particularly with actinium-225, citing better cancer cell retention and reduced toxicity to salivary and lacrimal glands compared to small molecules. He highlights promising early results from...
Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment - Emanuele Ostuni Details Oliver Sartor speaks with Emanuele Ostuni about ARTBIO’s focus on radiopharmaceuticals, particularly lead-212. Dr. Ostuni explains ARTBIO’s choice of lead-212 for its short half-life, which better matches the biological half-lives of targeting ligands. He discusses the manufacturing and distribution challenges associated with short-lived isotopes and outlines ARTBIO’s approach to developing a netw...